Ionizable Lipid Design Patents: Who Leads, White Space 2026
Ionizable Lipid Design: mapping the patents behind LNP delivery
25.3% concentration at the top. The five leading assignees together hold 3,022 of the 11,934 records in scope — a fifth-place holder still files 364, so the field is led but not closed. Annual filings moved from 543 records in 2017 to a peak of 1,574 in 2023, before the count for 2026 (143 so far) reflects an incomplete year rather than a real slowdown. The 2021-to-2024 span alone shows a 26% increase, the clearest complete-year growth signal in the data.
- 1MODERNATX INC9.6%
- 2BIONTECH SE4.7%
- 3MASSACHUSETTS INST OF TECH4.2%
- 4REGENERON PHARMACEUTICALS INC3.8%
- 5THE BROAD INST INC3.1%
See the full ionizable lipid design analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on ionizable lipid patents
How many patents exist for ionizable lipid design?
This landscape covers 11,934 published records between 2015 and mid-2026 that reference ionizable or cationic lipid chemistry alongside terms such as endosomal escape, biodegradable ester bonds, tail branching or lipid clearance. Filing volume rose from 543 records in 2017 to a peak of 1,574 in 2023. The 2025 and 2026 figures are still incomplete because publication typically lags actual filing by around 18 months, so the true current volume is higher than currently published counts show.
Who are the leading patent holders in ionizable lipid and LNP delivery?
The ranking covers 100 assignees, with the leader holding 1,140 records, well ahead of the fifth-place holder at 364 and the tenth-place holder at 179. The top five assignees combined account for 25.3% of all 11,934 records in scope, and the top ten for 35.1%, indicating a clear leader plus meaningful depth below it rather than a locked field. Strong co-assignee relationships also appear, most notably one academic-institution pairing that shares 324 records.
Where is the white space in ionizable lipid patents?
Composition data shows A61K medicinal-preparation claims and C12N genetic-engineering claims each cover more than half of all records, while C07D heterocyclic compounds (7.7%) and C07H sugars and nucleic acids (6.2%) are comparatively thin. That gap suggests structural chemistry around biodegradable ester linkages, tail branching and apparent pKa tuning for endosomal escape carries less claim density than broad formulation and delivery-vehicle filings, making it a more promising area to search for open claim space.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Ionizable Lipid Design covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.